Evangelia Sereti, MSc, PhD

home / authors / evangelia-sereti-msc-phd

Articles

Evangelia Sereti, MSc, PhD

Dr. Sereti on Addressing an Unmet Need With NOV202/Olaparib in BRCA1/2-Mutated Prostate Cancer

Evangelia Sereti, MSc, PhD
July 14th 2021

Evangelia Sereti, MSc, PhD, discusses the unmet need addressed with the addition of NOV202 to olaparib in BRCA1/2-mutated prostate cancer.

Read More

Evangelia Sereti, MSc, PhD, of Lund University Cancer Centre

Dr. Sereti on the Next Steps for NOV202 Plus Olaparib in BRCA1/2-Mutated Prostate Cancer

Evangelia Sereti, MSc, PhD
July 12th 2021

Evangelia Sereti, MSc, PhD, discusses the next steps with the combination of NOV202 and olaparib in BRCA1/2-mutated prostate cancer.

Read More

Evangelia Sereti, MSc, PhD, of Lund University Cancer Centre

Dr. Sereti on the Preclinical Efficacy of NOV202 Plus Olaparib in BRCA1/2-Mutated Prostate Cancer

Evangelia Sereti, MSc, PhD
July 10th 2021

Evangelia Sereti, MSc, PhD, discusses the preclinical efficacy of NOV202 plus olaparib in BRCA1/2-mutated prostate cancer cells.

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data